Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Burkitt Lymphoma × fludarabine phosphate × Clear all

Phase

Status

Sponsor Class

OTHER 66 NIH 6 OTHER_GOV 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9 Leukemia, Myeloid, Acute 7 Leukemia 5 Lymphoma 4 Leukemia, Biphenotypic, Acute 4 Myelodysplastic Syndromes 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia, B-Cell 2 Hodgkin Disease 2 Head and Neck Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Anemia, Refractory, with Excess of Blasts 2 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1

Interventions

tisagenlecleucel 7 Cyclophosphamide 6 fludarabine 4 blinatumomab 4 aflibercept 4 ibrutinib 2 epratuzumab 2 Vincristine 2 Radioimmunodetection 2 Methotrexate 2 MLN 8237 2 Inotuzumab Ozogamicin 2 tafasitamab 1 sepantronium 1 ruxolitinib 1 relatlimab 1 pembrolizumab 1 pegaspargase 1 ontuxizumab 1 obinutuzumab 1 loncastuximab tesirine 1 forodesine 1 fludarabine phosphate 1 fiu protein, E coli 1 exatecan 1 brexucabtagene autoleucel 1 asparaginase erwinia chrysanthemi recombinant 1 acalabrutinib 1 Thioguanine 1 Rituximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06009107 2025-08-08

B-ALL

Juventas Cell Therapy Ltd.

Phase 1/2 Withdrawn

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡